Canadian Sec - Free Realtime Quote CAD

Pharmala Biotech Holdings Inc. (MDMA.CN)

0.1600

+0.0050

+(3.23%)

As of 1:44:16 PM EDT. Market Open.

PharmAla Contracts with Partner to Act as US Distributor

TORONTO, March 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has contracted with a third party logistics company specializing in pharmaceutical products to act as its US clinical trial distribution partner. “PharmAla has noted over the past months that US-Canad

GlobeNewswire 22 days ago

MDXXF
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington

TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to the University of Washington, USA. This continues the fulfillment of orders from important human research studies in the United S

GlobeNewswire 25 days ago

MDXXF
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has signed a distribution agreement with Duchefa Farma B.V. (“Duchefa”) of Haarlem, Netherlands, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. “Last year, the Du

GlobeNewswire last month

MDXXF
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has completed its. The Company believes this is the first such shipment of MDMA capsules to cross the American/Canadian border. “We are incredibly pleased to have delivered our clinical trial material

GlobeNewswire last month

MDXXF
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that its previously announced (See press release of October 8, 2024) contract to the University of Texas Health Science Center at San Antonio (UT Health San Antonio) will move forward, with the trial h

GlobeNewswire last month

MDXXF
PharmAla Issues Q1 Financial Statements

TORONTO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the year ended November 30, 2024. All figures are reported in Canadian dollars. The Company’s full set of consolidated audited financial statemen

GlobeNewswire 2 months ago

MDXXF
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel

TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Merhavim Mental Health Centre of Beer Yaakov, Israel (“Merhavim”). All data generated in the clinical trial, entitled “MDMA Assisted Psychotherapy for PTSD of E

GlobeNewswire 2 months ago

MDXXF
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement

TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its financial and operational results for the year ended August 31, 2024, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company’s full

GlobeNewswire 3 months ago

MDXXF
PharmAla Announces Private Placement

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its intention to complete a non-brokered private placement offering of units of the Company (each, a “Unit”) at a price of $0.18 per Unit for aggregate gross proceeds of $1,400,000 (the “Offering”)

GlobeNewswire 3 months ago

MDXXF
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License

TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has signed a Letter of Intent with a research institution to provide its LaNeo MDMA in exchange for a full and perpetual license to the efficacy and safety data generated by the trial. “One of the benefits of having a stro

GlobeNewswire 4 months ago

MDXXF
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale

TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Yale University. “Requests for clinical trial material – LaNeo™ MDMA – for research purposes continues to occupy the Company at

GlobeNewswire 5 months ago

MDXXF
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA

TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is excited to announce that it has been contracted as a supplier of its GMP LaNeo™ MDMA to a clinical trial at Mt. Sinai Health System. “We’re looking forward to supporting the team at Mt. Sinai Health System with high qua

GlobeNewswire 5 months ago

MDXXF
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA

TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a proposed clinical trial at the University of Texas, San Antonio. Pursuant to a submitted grant funding application by the principals, the contrac

GlobeNewswire 6 months ago

MDXXF
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA

TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Harvard’s Maclean Hospital, the largest neuroscientific and psychiatric private research hospital in the world. “As has recently

GlobeNewswire 6 months ago

MDXXF
PharmAla to supply Johns Hopkins Medicine for Clinical Trial

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Johns Hopkins Medicine. “We’re looking forward to continuing to provide exceptional service – as well as robust investigational

GlobeNewswire 6 months ago

MDXXF
PharmAla Launches MDMA Clinical Trial Tool for Researchers

TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has created a new tool for researchers, providing direct access to its Chemistry, Manufacturing and Control (CMC) data – as well as its investigator’s brochure – to qualified researchers. “Ov

GlobeNewswire 7 months ago

MDXXF
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request that Lykos Therapeutics complete a third confirmatory Phase 3 trial prior to allowing the approval of MDMA assisted therapy (MDM

GlobeNewswire 8 months ago

MDXXF
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to share its Q3 Financial Statement. The 9 months ended May 31st, 2024, included significant revenue growth compared to the previous year. “I am pleased to report that, as compared to the same period in 2023, Ph

GlobeNewswire 8 months ago

MDXXF
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has officially launched its Prescribers Portal for medical practitioners with prescribing power to learn more about MDMA, its effects, and the potential ability to access the molecule for thei

GlobeNewswire 11 months ago

MDXXF
PharmAla Closes Private Placement and Concurrent Debt Settlement

VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, further to its press release dated April 10, 2024 (the “April 10 Release”), the Company has closed its previously announced non-brokered private placement offering (the “O

GlobeNewswire 11 months ago

MDXXF

Performance Overview

Return	MDMA.CN	S&P/TSX Composite index (^GSPTSE)
YTD	-28.89%	-2.50%
1-Year	-20.00%	+10.42%
3-Year	+300.00%	+9.84%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pharmala Biotech Holdings Inc. (MDMA.CN)

PharmAla Contracts with Partner to Act as US Distributor

PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington

PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands

PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study

PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA

PharmAla Issues Q1 Financial Statements

PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel

PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement

PharmAla Announces Private Placement

PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License

PharmAla to supply LaNeo MDMA for Clinical Trial at Yale

PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA

PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA

PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA

PharmAla to supply Johns Hopkins Medicine for Clinical Trial

PharmAla Launches MDMA Clinical Trial Tool for Researchers

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement

PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

PharmAla Closes Private Placement and Concurrent Debt Settlement

Performance Overview